Immunovia publ AB (IMMNOV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immunovia publ AB (IMMNOV) has a cash flow conversion efficiency ratio of -0.306x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-19.78 Million ≈ $-2.13 Million USD) by net assets (Skr64.73 Million ≈ $6.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Immunovia publ AB - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Immunovia publ AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Immunovia publ AB total liabilities for a breakdown of total debt and financial obligations.
Immunovia publ AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunovia publ AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fitters Diversified Bhd
KLSE:9318
|
0.027x |
|
Giga Media Ltd
NASDAQ:GIGM
|
0.001x |
|
Relpol SA
WAR:RLP
|
0.020x |
|
Inbest Prime VII Inmuebles SOCIMI S.A.
MC:YINB7
|
0.011x |
|
Samil Co.Ltd
KQ:032280
|
0.015x |
|
Way 2 Vat Ltd
AU:W2V
|
-1.805x |
|
CADOGAN ENERGY SOLUTIONS
F:CPD
|
N/A |
|
Genmin Ltd
AU:GEN
|
-0.213x |
Annual Cash Flow Conversion Efficiency for Immunovia publ AB (2013–2025)
The table below shows the annual cash flow conversion efficiency of Immunovia publ AB from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Immunovia publ AB stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr64.73 Million ≈ $6.97 Million |
Skr-78.40 Million ≈ $-8.44 Million |
-1.211x | +85.42% |
| 2024-12-31 | Skr11.65 Million ≈ $1.25 Million |
Skr-96.75 Million ≈ $-10.41 Million |
-8.306x | -278.36% |
| 2023-12-31 | Skr66.99 Million ≈ $7.21 Million |
Skr-147.06 Million ≈ $-15.83 Million |
-2.195x | -204.81% |
| 2022-12-31 | Skr243.80 Million ≈ $26.24 Million |
Skr-175.58 Million ≈ $-18.90 Million |
-0.720x | -104.71% |
| 2021-12-31 | Skr433.90 Million ≈ $46.70 Million |
Skr-152.65 Million ≈ $-16.43 Million |
-0.352x | -74.70% |
| 2020-12-31 | Skr599.40 Million ≈ $64.51 Million |
Skr-120.70 Million ≈ $-12.99 Million |
-0.201x | +21.68% |
| 2019-12-31 | Skr357.61 Million ≈ $38.48 Million |
Skr-91.95 Million ≈ $-9.90 Million |
-0.257x | -41.22% |
| 2018-12-31 | Skr461.95 Million ≈ $49.71 Million |
Skr-84.11 Million ≈ $-9.05 Million |
-0.182x | +6.91% |
| 2017-12-31 | Skr236.80 Million ≈ $25.48 Million |
Skr-46.32 Million ≈ $-4.98 Million |
-0.196x | -355.98% |
| 2016-12-31 | Skr276.63 Million ≈ $29.77 Million |
Skr-11.87 Million ≈ $-1.28 Million |
-0.043x | -26.43% |
| 2015-12-31 | Skr83.80 Million ≈ $9.02 Million |
Skr-2.84 Million ≈ $-305.99K |
-0.034x | +85.37% |
| 2014-12-31 | Skr35.74 Million ≈ $3.85 Million |
Skr-8.29 Million ≈ $-892.20K |
-0.232x | -176.53% |
| 2013-12-31 | Skr4.94 Million ≈ $531.55K |
Skr-414.31K ≈ $-44.59K |
-0.084x | -- |
About Immunovia publ AB
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.